Hendree E Jones
Overview
Explore the profile of Hendree E Jones including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
204
Citations
3075
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu K, Bello J, Buss J, Jones H, Bierut L, Stwalley D, et al.
Addict Sci Clin Pract
. 2025 Mar;
20(1):24.
PMID: 40065369
No abstract available.
2.
Burduli E, Landis T, Brumley C, Kenefick L, Paulsgrove K, Jones H, et al.
J Subst Use Addict Treat
. 2025 Feb;
172:209644.
PMID: 39986389
Introduction: The rise in fentanyl use during pregnancy has created new challenges in caring for women with opioid use disorders (OUD) and their infants with neonatal abstinence syndrome or neonatal...
3.
Sousa A, Besong O, Wachman E, Taglauer E, Beane J, Kefella Y, et al.
Placenta
. 2025 Feb;
162:27-34.
PMID: 39983471
Introduction: Opioid exposure during pregnancy may significantly alter gene expression in the placenta, potentially disrupting its function and influencing fetal brain development. These alterations may contribute to adverse outcomes such...
4.
Xu K, Jones H, Martin C, Smid M, Tiako M, Terplan M, et al.
J Addict Med
. 2025 Feb;
PMID: 39960779
Background: Substance use is a leading cause of pregnancy-associated death in the US. It is not known if the amount of perinatal content at national addiction science conferences reflects the...
5.
Peltier M, Pegram D, Chander G, Weisner C, McKee S, Jones H, et al.
J Womens Health (Larchmt)
. 2025 Feb;
PMID: 39932704
Despite increased initiatives and funding to improve access to evidence-based treatments for opioid use disorder (OUD), including medications for OUD (mOUD), pregnant/postpartum individuals have significant obstacles to accessing these life-saving...
6.
Xu K, Bello J, Buss J, Jones H, Bierut L, Stwalley D, et al.
Addict Sci Clin Pract
. 2025 Jan;
20(1):1.
PMID: 39762993
Background: The postpartum period provides an opportunity for birthing people with opioid use disorder (OUD) to consider their future reproductive health goals. However, the relationship between the use of medication...
7.
Xu K, Berkel T, Martin C, Jones H, Carter E, Kelly J, et al.
Nat Ment Health
. 2024 Dec;
2(7):801-808.
PMID: 39726823
While attention deficit hyperactivity disorder is common among people with addiction, the risks and benefits of attention deficit hyperactivity disorder medication in pregnant people with opioid use disorder are poorly...
8.
Burduli E, Jones H
Semin Perinatol
. 2024 Dec;
49(1):152010.
PMID: 39648070
The long-term outcomes of children exposed to opioids and other substances in utero, specifically those diagnosed with Neonatal Abstinence Syndrome (NAS), present a complex interaction of different factors. First, NAS...
9.
Kounlavong E, Schauberger C, Conklin J, Jones H
J Addict Med
. 2024 Nov;
19(2):121-128.
PMID: 39514890
Objectives: Inhalants are often used for their psychoactive effects, producing feelings of euphoria. Inhalant and solvent use is a serious public health concern, yet little is known about their effects...
10.
Straub L, Bateman B, Hernandez-Diaz S, Zhu Y, Suarez E, Vine S, et al.
JAMA
. 2024 Aug;
332(10):805-816.
PMID: 39133511
Importance: Buprenorphine combined with naloxone is commonly used to treat opioid use disorders outside of pregnancy. In pregnancy, buprenorphine alone is generally recommended because of limited perinatal safety data on...